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Abstract
Background Bilateral adrenalectomy (BLA) is a treat-
ment option to alleviate symptoms in patients with ectopic
Cushing’s syndrome (ECS) for whom surgical treatment of
the responsible nonpituitary tumor is not possible. ECS
patients have an increased risk for complications, because
of high cortisol levels, poor clinical condition, and meta-
bolic disturbances. This study aims to evaluate the safety
and long-term efficacy of endoscopic BLA for ECS.
Methods From 1990 to present, 38 patients were diag-
nosed and treated for ECS in the Erasmus University
Medical Center, a tertiary referral center. Twenty-four
patients were treated with BLA (21 endoscopic, 3 open), 9
patients were treated medically, and 5 patients could be
cured by complete resection of the adrenocorticotropic
hormone (ACTH)-producing tumor. The medical records
were retrospectively reviewed and entered into a database.
For evaluation of the efficacy of BLA, preoperative bio-
chemical and physical symptoms were assessed and com-
pared with postoperative data.
Results Endoscopic BLA was successfully completed in
20 of the 21 patients; one required conversion to open
BLA. Intraoperative complications occurred in two (10%)
patients, and postoperative complications occurred in three
(14%) patients. Median hospitalization was 9 (2–95) days,
and median operating time was 246 (205–347) min.
Hypercortisolism was resolved in all patients. Improve-
ments of hypertension, body weight, Cushingoid appear-
ance, impaired muscle strength, and ankle edema were
achieved in 87, 90, 65, 61, and 78% of the patients,
respectively. Resolution of diabetes, hypokalemia, and
metabolic alkalosis was achieved in 33, 89, and 80%,
respectively.
Conclusion Endoscopic BLA is a safe and effective
treatment for patients with ectopic Cushing’s syndrome.
Keywords Bilateral adrenalectomy  Endoscopic 
Cushing’s syndrome  Ectopic
Hypercortisolism in Cushing’s syndrome (CS) is usually
caused by a corticotropin (ACTH)-producing pituitary
tumor (Cushing’s disease). Other causes of CS are cortisol
secretion by an adrenal adenoma/carcinoma or ACTH
hypersecretion by a nonpituitary tumor (ectopic Cushing’s
syndrome) [1]. The incidence of this disorder is more
common in women than in men and ranges from 0.7 to 2.4
per million population per year [2, 3]. Ectopic ACTH
secretion and, rarely, ectopic corticotropin-releasing hor-
mone (CRH) secretion are responsible for 10–20% of cases
of CS [4]. It may be caused by a wide spectrum of tumors,
ranging from undetectable tumors (occult CS) to wide-
spread metastatic disease. However, the majority of
patients with ectopic Cushing’s syndrome (ECS) suffer
from disseminated malignant disease. In ECS, circulating
ACTH and cortisol levels may increase to notably high
levels over a short period of time (less than 3 months). The
main symptoms of ECS are mineralocorticoid disturbances,
metabolic disturbances, hypertension, diabetes mellitus,
and psychiatric problems. Patients may suffer from severe
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infections and life-threatening sepsis due to immunosup-
pression. Treatment should be directed, whenever possible,
at the primary cause of the ACTH hypersecretion. Unfor-
tunately, the ACTH-producing tumor cannot always be
found or is not resectable, which is the case in widespread
metastatic disease [5]. Bilateral adrenalectomy (BLA) is an
option for patients with ECS for whom surgical treatment
of the primary cause is not possible. The procedure may be
technically demanding, but mortality and morbidity are
low provided the procedure is performed by a skilled sur-
gical team and the endoscopic technique is utilized [6–8].
After its initial description in 1992 [9], the endoscopic
technique has become widely accepted and is now the
standard of care for benign adrenal tumors. However, the
efficacy and safety of endoscopic BLA in patients with
ECS remain unclear. ECS patients represent a group at
high risk for complications. This is caused not only by
severe hypercortisolism and higher prevalence of hypoka-
lemia but also by the poor clinical condition of these
patients [10]. This study aims to evaluate the safety and
long-term efficacy of endoscopic BLA for ECS by
reviewing long-term data from a large series of ECS
patients operated on in a single tertiary referral center.
Patients and methods
ECS was defined as ACTH-dependent Cushing’s syndrome
caused by ACTH production by tumors other than a pitu-
itary tumor. All patients who were diagnosed with ECS
from 1990 to present at Erasmus MC, a tertiary referral
center, were entered into a database. The medical records
of these patients were retrospectively reviewed. Patient
demographics, location of ACTH-producing tumor, labo-
ratory results, radiological and 111In-pentetreotide scintig-
raphy (OctreoScan) findings, results of other imaging
modalities or localizing studies, earlier treatment modali-
ties, perioperative variables, pathology, complications,
length of stay, and mortality were collected from medical
records and the municipality register. All patients contin-
ued to visit Erasmus MC routinely after diagnosis and
treatment of ECS. Solely patients being cured by radical
resection of an ACTH-producing tumor were later dis-
charged from follow-up.
For evaluation of efficacy, preoperative biochemical and
physical symptoms were assessed and compared with
postoperative data in addition to long-term outcomes.
Special attention was directed to mineralocorticoid/meta-
bolic disturbances, blood pressure, and physical Cushing’s
syndrome symptoms (moon face, buffalo hump, increased
body weight, decreased muscle strength, and edema).
Endoscopic BLA was performed through retroperito-
neal or transperitoneal approach. Endoscopic BLA was
considered successful if conversion to an open procedure
was not needed and cortisol levels were diminished.
Statistical analysis was carried out using SPSS (version
15.0.0). Data are reported as median (range) or mean
(±standard deviation, SD) as appropriate. Categorical data
are reported as counts (percentage).
Results
Thirty-eight patients were diagnosed with ECS. Mean age
at diagnosis was 50.4 (±11.7) years. Twenty-three (61%)
patients were female, and 15 (39%) were male. Of these 38
patients, 24 (63%) patients underwent BLA (21 endo-
scopic, 3 open BLA). Nine (23%) patients were treated
medically, and 5 (13%) underwent complete resection of
the primary tumor at a later stage. Ten patients (one
curative excluded) were diagnosed and treated for ECS
before introducing endoscopic BLA, with median survival
of 10.5 (0.8–137) months. After introducing endoscopic
BLA, 23 (4 curative excluded) patients were diagnosed and
treated with median survival of 15.3 (0.3–176) months.
Patient characteristics are presented in Table 1. Besides
elevated serum ACTH, serum cortisol, and urine free-
cortisol levels, the majority of patients suffered from
hypokalemia. Metastatic disease was found in most
patients with ECS. Liver metastases were most common,
being present in 12 (32%) patients.
Medical and curative treatment
The nature of the ACTH-producing tumors that were
treated medically or cured by complete resection is listed in
Table 2. All medically treated patients died, with median
survival of 1.5 (0.3–57) months. All patients cured by
complete resection are currently alive, with median follow-
up of 111 (23–203) months and no signs of recurrence. All
patients who were cured by radical resection of the primary
tumor had nonmetastatic bronchial carcinoid.
Bilateral adrenalectomy
Median follow-up in patients treated with BLA was 38
(11–176) months. Median survival of patients undergoing
BLA for ECS was 14.5 (0.8–83) months. The nature of the
ACTH-producing tumors of the patients treated by BLA, as
well as median survival rates, are listed in Table 3.
Nine (38%) of the 24 patients who underwent BLA are
still alive, while 15 (62%) patients have died. Patients with
an unknown site of ACTH-producing tumor represent the
largest group. Four out of five patients are currently alive
while the location of the primary tumor remains unclear.
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The diagnosis of ECS in these patients was made on the
basis of inferior petrosal sampling for ACTH before and
after administration of CRH, negative magnetic resonance
imaging (MRI) of the pituitary, and/or determination of
circulating CRH levels.
Endoscopic bilateral adrenalectomy
Twenty-one of 24 patients who underwent BLA had an
endoscopic procedure. Open procedures were performed
in three patients. Two patients were treated before the
Table 1 ECS patient
characteristics
Parameter BLA Medical treatment Complete resection
of primary tumor
N 24 9 5
Gender (female/male) 15/9 5/4 3/2
Age at diagnosis (years) 52.3 (21.4–65.5) 45.6 (34.9–77.9) 40.1 (35.8–67.6)
ACTH at diagnosis (ng/l) 282 (69–1,371) 114 (82–1,930) 104 (67–304)
Morning plasma cortisol
at diagnosis (mmol/l)
2,480 (706–27,573) 1,680 (878–5,097) 1,381 (811–3,500)
Cortisoluria at diagnosis
(mmol/24 h)
12,704 (1,127–96,674) 10,456 (1,260–45,818) 4,653 (2,419–10,450)
Hypokalemia (\3.5 mmol/l) 17 (85%) 6 (66%) 4 (80%)
Primary tumor resection 5 (21%) 3 (33%) 5 (100%)
Metastatic disease 17 (70%) 9 (100%) 0
Liver 9 (38%) 3 (33%) 0
Local lymph nodes 3 (13%) 4 (44%) 0
Bone 4 (17%) 1 (11%) 0
Brain 1 (4%) 1 (11%) 0
Table 2 Medical and curative














4 10 (1.5–57) 0 NA
Small cell lung cancer 3 0.5 (0.4–0.8) 0 NA
Pancreatic endocrine
tumor
1 1.5 0 NA
Thymic carcinoid 1 3.5 0 NA
Bronchial carcinoid 0 NA 5 111 (23–203)













All patients 24 9 (38%) 38 (11–176) 15 (62%) 14.5 (0.8–83)
Unknown primary tumor 5 4 (80%) 55 (25–138) 1 (20%) 11
Bronchial carcinoid 4 1 (25%) 138 3 (75%) 6.7 (6–9.5)
Disseminated neuroendocrine
tumor
4 2 (50%) 13 (11–15) 2 (50%) 18 (12–23)
Medullary thyroid cancer 3 1 (33%) 25 2 (66%) 19.5 (18–21)
Pancreatic endocrine tumor 3 0 NA 3 (100%) 19.5 (14.5–35)
Prostate endocrine tumor 2 0 NA 2 (100%) 1.5 (0.8–2.5)
Gastric carcinoid 1 1 (100%) 176 0 NA
Thymic carcinoid 1 0 NA 1 (100%) 83
Esthesioneuroblastoma 1 0 NA 1 (100%) 31.5
NA not available
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introduction of endoscopic BLA in our hospital, and a
laparoscopic procedure was contraindicated in one patient
because of poor cardiopulmonary condition; it was not
possible to create a pneumoperitoneum in this patient.
Eleven procedures were transperitoneal and 10 were ret-
roperitoneal. Fourteen women and seven men were trea-
ted, with mean age of 52.1 (±10.9) years. Median body
mass index (BMI) was 25.6 (16.3–29.1) kg/m2. Median
adrenal weight was 21 (10.4–37) g. Histology reports
noted diffuse adrenal hyperplasia in 15 (71%) patients,
nodular hyperplasia in 5 (24%) patients, and normal,
nonpathologic adrenal tissue in 1 (5%) patient. Endoscopic
procedures were performed with median operating time of
246 (205–347) min. Median hospital stay was 9 (2–95)
days. All patients achieved biochemical resolution of
hypercortisolism. Conversion was necessary in one
patient, caused by limited view due to hepatomegaly.
Complications occurred in five (24%) patients. Two (10%)
complications were intraoperative, and three (14%) were
postoperative. In one patient, the spleen and colon were
accidentally injured. The patient underwent relaparotomy;
the spleen was removed, and a segment of the injured
colon was resected. The patient fully recovered afterwards.
The other patient experienced severe hypokalemia peri-
operatively, which could be treated successfully. Postop-
erative complications were pulmonary embolisms in two
patients, further complicated by myocardial infarction in
one of these patients and pneumonia in the other. Both
patients recovered without further consequences. One
patient had an intra-abdominal infected hematoma and
perforation of a duodenal ulcer. This patient was in very
poor clinical condition preoperatively, which deteriorated
further due to the complications. The patient eventually
died 28 days after surgery. Out of 21 patients who
underwent endoscopic BLA, 13 patients died, with median
survival of 14 (0.8–83) months. Eight patients are cur-
rently alive, with median follow-up of 32 (11–176)
months.
Clinical symptoms
Changes in clinical symptoms are presented in Table 4.
Two out of 21 patients treated by endoscopic BLA died
shortly after the operation, leaving 19 patients suitable for
further assessment. Hypertension (C140/90 mmHg or
antihypertensive medication) was resolved or decreased in
86% of patients. In five patients (50%) antihypertensive
medication could be stopped, and in three (30%) patients a
decreased dosage was sufficient to control systolic and
diastolic blood pressures. Among those patients with
BMI C25 kg/m2, BMI decreased to less than 25 kg/m2 in
nine (90%) patients. Cushingoid appearance disappeared or
improved in 11 (65%) patients. Impaired muscle strength
resolved or improved in eight (62%) patients. Ankle edema
resolved or improved in 11 (78%) patients.
Biochemical symptoms
The result of endoscopic BLA with regard to biochemical
test results is listed in Table 5. In 13 (72%) patients dia-
betes was resolved or improved after operation. Among
patients having mild to severe hypokalemia (B3.4 nmol/l)
preoperatively, 17 (89%) patients had normal serum
potassium levels postoperatively and in 2 (11%) patients
potassium levels improved. Potassium substitution could
be stopped for the entire group of patients. Alkalosis
resolved in 12 (80%) patients and improved in 2 (13%)
patients enduring metabolic alkalosis preoperatively.
Discussion
The current study shows that endoscopic bilateral adre-
nalectomy is an efficient and safe technique for treatment
of ECS. Many malignancies causing ECS are associated
with relatively prolonged survival. However, to be con-
sidered for prolonged survival, control of severe and rela-
tively acute hypercortisolism is mandatory. Effective and
definitive ECS symptom control can be achieved by
endoscopic BLA. Nonetheless, the complication rate may
be higher in ECS patients than in patients treated for benign
adrenal disease or Cushing’s disease.
This study is the first to evaluate the efficacy and safety
of endoscopic BLA in ECS patients specifically, while
other studies evaluated the safety and effectiveness of
endoscopic BLA in patients with refractory Cushing’s
disease. Some of these studies included a limited number
of ECS patients [6, 7, 11–13]. Our study is the first to
show that endoscopic BLA can be successfully performed
in 95% of ECS patients. Most patients suffered from
physical symptoms, hypokalemia, hypertension, diabetes,
and metabolic alkalosis. These symptoms were resolved or
showed significant improvement in the majority of
patients.
Table 4 Clinical symptoms after endoscopic BLA






Hypertension 15 (78) 13 (87) 2 (13)
BMI (C25 kg/m2) 10 (53) 9 (90) 1 (10)
Cushingoid
appearance
17 (89) 11 (65) 6 (35)
Impaired muscle
strength
13 (68) 8 (62) 5 (38)
Ankle edema 14 (74) 11 (78) 3 (22)
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In our hospital, endoscopic BLA was introduced in
1996. During the period from 1990 to 1996, 11 patients
were diagnosed with ECS. Two (18%) patients were trea-
ted with open bilateral adrenalectomy. In the period
between 1996 and 2010, 27 patients were diagnosed with
ECS, of whom 22 (76%) were treated with BLA (21
endoscopic, 1 open). This illustrates that the choice
between medical treatment and BLA has shifted towards
BLA since the introduction of endoscopic BLA. This may
be caused by the perception that decreased surgical trauma
in endoscopic BLA makes this approach more attractive for
patients in poor clinical condition [14].
The retrospective nature of this study makes valid
comparison of medical versus surgical treatment difficult,
due to selection bias. Indeed, patients who were treated
medically were in poorer condition and always had distant
metastases. This is illustrated by the fact these patients had
median survival of 1.5 months. The longer the predicted
survival, the more important it is to control hypercortisol-
ism. Therefore, patients in better clinical condition were
selected for surgery. However, since medical therapy was
not different before and after 1996, the positive effect of
surgery as standard therapy for ECS can be evaluated by
comparing the median survival before and after the intro-
duction of endoscopic BLA. Although the results are not
significant [10.5 (0.8–137) vs. 15.3 (0.3–176) months],
they may suggest a small benefit in survival in favor of
patients treated after introducing endoscopic BLA. How-
ever, this comparison must be interpreted with caution, as
data are compared from different time periods, carrying the
risk of introducing other variables (such as the level of care
available at the time) that may not be measurable at the
time of evaluation. Patients with CS are at higher risk for
complications by reason of obesity, impaired wound
healing, immunosuppression, and increased risk of throm-
boembolism compared with patients undergoing adrenal-
ectomy for diseases other than CS [15, 16]. Complications
are reported in 8–14% of patients undergoing endoscopic
BLA for CS [6, 7, 12, 13]. Patients with ECS are known to
have extreme and acute hypercortisolism, and higher
prevalence of hypokalemia [10]. This may account for a
higher complication rate in patients with ECS. Surpris-
ingly, no wound infections were found.
Obesity was suggested to be a risk factor for perioper-
ative complications and conversion in several studies, as it
makes identification of anatomy and dissection more dif-
ficult [13]. The median BMI in our series was 25.4
(16.3–29.1) kg/m2, which is low in comparison with other
studies considering patients with refractory Cushing’s
disease [12, 13]. This relatively low BMI may be explained
by the rapid onset of hypercortisolism in patients with ECS.
The transperitoneal approach was performed in 11
(52%) patients and the retroperitoneal endoscopic approach
in 10 (48%) patients. Transperitoneal adrenalectomy is the
most common approach for endoscopic adrenalectomy
worldwide and is currently the approach of choice in our
institute as well. Before 2004, endoscopic BLA was per-
formed by using the retroperitoneal approach. After that,
BLA was performed transperitoneally. This transition was
due to the fact that other surgeons became responsible for
the adrenalectomies, preferring the transperitoneal
approach. Each approach has different advantages for
patients with ECS. The transperitoneal approach provides
good exposure and the availability of landmarks, and offers
the opportunity to check the abdominal cavity for pathol-
ogy and metastases. However, at the same time this
approach has higher risk for accidental injury of intra-
abdominal organs. The retroperitoneal approach is fast,
safe, and avoids intraoperative difficulties due to adhesions
[17]. Moreover, the retroperitoneal approach avoids the
need for repositioning during the procedure. This provides
the possibility to resect both adrenals concurrently. A
disadvantage of the retroperitoneal approach is the limited
working area, which makes this procedure technically more
demanding. In our series, intraoperative and postoperative
complications occurred equally with both approaches, and
operating time was the same. This is in line with com-
parisons of the two techniques that showed no significant
differences in outcome [18, 19].
ECS is a heterogeneous disease. Its cause varies from
small localized tumors, which are sometimes occult, to
severe malignant tumors with widespread metastases,
mainly in the liver and local lymph nodes. Prognosis and
treatment options differ from patient to patient, depending
on the source and extent of the disease. In our series,




Biochemical symptom In patients (%) Resolved (%) Improvement (%) No change (%)
Diabetes mellitus 18 (86) 6 (33) 7 (39%) 5 (27%)
Hypokalemia 19 (90) 17 (89) 2 (11%) 0
Potassium supplementation
needed
13 (62) 13 (100) 0 0
Metabolic alkalosis 15 (71) 12 (80) 2 (13%) 1 (7%)
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ACTH secretion, similar to in other studies reported in the
literature [5, 20–22]. Medullary thyroid carcinoma was the
second most frequent cause (18% of ECS patients). This is
a high percentage compared with most other studies,
probably caused by the fact that our hospital is a tertiary
referral center for multiple endocrine neoplasia (MEN) II
syndrome and complex thyroid carcinoma patients. Con-
versely, small cell lung cancer only accounted for 8% of
patients in our series, compared with up to 50% in the
literature [2, 20–22].
In conclusion, we state that endoscopic BLA is a safe
and effective treatment for patients with ectopic Cushing’s
syndrome who cannot be treated by radical resection of the
primary tumor. However, the risk of complications may be
relatively high compared with patients undergoing endo-
scopic BLA for other causes of Cushing’s syndrome. This
may be explained by the poor clinical condition of these
patients caused by metastasized disease, which often
deteriorates further due to ectopic Cushing’s syndrome.
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